Efficacy and safety of a first-in-class inhaled PDE3/4 inhibitor (ensifentrine) vs salbutamol in asthma
ConclusionsSingle-dose ensifentrine demonstrated dose-dependent bronchodilation, and was as effective as a therapeutic dose of nebulised salbutamol. All ensifentrine doses were similarly well tolerated, and did not show the characteristic β2-agonist systemic adverse effects.
Source: Pulmonary Pharmacology and Therapeutics - Category: Respiratory Medicine Source Type: research
More News: Asthma | Cardiology | Drugs & Pharmacology | Heart | Potassium | Respiratory Medicine | Study